Posted by Michael Wonder on 01 Dec 2020
ICER releases draft evidence report on therapies for anaemia in chronic kidney disease
30 November 2020 - Public comment period now open until 5 January 2021; requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review (ICER) today released a draft evidence report assessing the comparative clinical effectiveness and value of treatments for roxadustat (AstraZeneca) for treatment of anaemia in chronic kidney disease.
This preliminary draft marks the midpoint of ICER’s eight month process of assessing these treatments, and the findings within this document should not be interpreted to be ICER’s final conclusions.
